Navigation Links
Agendia's MammaPrint(R) Receives Prestigious Award From Dutch Innovation Platform
Date:6/26/2008

Test Declared One of the Most Pioneering Healthcare Innovations in 21st

Century

AMSTERDAM, Netherlands, June 26 /PRNewswire/ -- Agendia BV, a world leader in gene expression analysis-based diagnostics, is pleased to announce that the company recently received a prestigious award for its groundbreaking MammaPrint(R) test from the Dutch Innovation Platform. MammaPrint, a 70-gene signature diagnostic test that predicts high or low risk of breast cancer tumor recurrence, was chosen out of more than 150 entries as the most pioneering healthcare initiative and will have the distinguished honor of being actively supported at a national level by the Dutch government.

"We are honored that the value of MammaPrint has been recognized at a governmental level for its significant impact on the management of breast cancer," said Dr. Bernhard Sixt, president and chief executive officer of Agendia. "This award provides us with the national support that will ensure that even more breast cancer patients will benefit from personalized treatment."

MammaPrint was among four healthcare innovations awarded by Dutch Health Minister Ab Klink, chairman of the Healthcare Innovation Platform, at a recent Netherlands-based Healthcare summit. The Innovation Platform is the government's initiative dedicated to advancing The Netherlands toward becoming one of the top five international countries in the areas of higher education, research and innovation by creating the conditions, establishing the connections, and developing the vision required to stimulate innovation and entrepreneurship.

"Each year, more than 13,000 women are diagnosed with breast cancer in The Netherlands, with another 317,000 diagnosed throughout Europe and nearly 180,000 diagnosed in the United States," said Richard Bender, MD, FACP, Agendia's chief medical officer. "At Agendia, we are committed to making a positive impact on the health and quality of life of people suffering from cancer, and new technologies like MammaPrint are changing the way oncologists are treating this life-threatening disease in a way that directly benefits patients' lives."

As part of the recognition and support surrounding the award, Minister Klink noted that he would actively support the inclusion of MammaPrint in the package of treatments for which reimbursement is available so that the test can provide benefit to as many breast cancer patients as possible in The Netherlands.

About MammaPrint(R)

MammaPrint laboratory service is the first and only FDA cleared (February 2007) DNA microarray-based 'in vitro diagnostic multivariate index assay' (IVDMIA). MammaPrint measures the activity of 70 genes, providing information about the likelihood of tumor recurrence. The MammaPrint test measures the level of expression of each of these genes in a sample of a woman's surgically-removed breast cancer tumor and then uses a specific formula or algorithm to produce a score that determines whether the patient is deemed low risk or high risk for spread of the cancer to another site. The result may help a doctor in planning treatment and appropriate follow-up for a patient when used with other clinical information and laboratory tests. All MammaPrint tests are conducted in Agendia's CLIA-certified central service laboratory.

About Agendia

Agendia, located in Amsterdam, The Netherlands, is a world leader in gene expression analysis-based diagnostics with three products on the market. The company focuses on the development and commercialization of diagnostic tests using tumor gene expression profiling. Agendia was the first company to commercialize a prognostic test - MammaPrint(R) - that predicts the risk of breast cancer recurrence. Agendia maintains close ties with several leading academic centers to develop state of the art diagnostic tests for cancer. Agendia also offers its expertise to pharma companies focusing on development of highly effective personalized drugs in the area of oncology. For more information on Agendia, please visit http://www.agendia.com.

* CupPrint(R) is based on a license to the TUO database of AviaraDx

MEDIA CONTACTS:

For Agendia - EU & non-U.S.-based Media:

Dr. Bernhard Sixt

President and Chief Executive Officer

Agendia

+31204621520

communications@agendia.com

For Agendia - U.S. Media:

Kelly Connor

Vice President

Ogilvy Public Relations Worldwide

+1.212.880.5328 Office

+1.609.221.5785 Mobile

Kelly.connor@ogilvypr.com


'/>"/>
SOURCE Agendia BV
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. MammaPrint(R) Breast Cancer Test Provides Valuable Insight for Personalized Treatment Decisions
2. MammaPrint(R) Breast Cancer Test Validated in Lymph Node-Positive Breast Cancer Patients
3. TraumaCure Receives Prestigious ISO 13485 Certification
4. Kiwa Bio-Tech Receives Authorization From the Ministry of Commerce of the Peoples Republic of China to Wholesale Other Fertilizer Manufacturers Products
5. TraumaCure Receives Prestigious ISO 13485 Certification
6. Advance Nanotechs Owlstone Subsidiary Receives a $629,000 Order From Selex Galileo
7. WorldHeart Enters into a Recapitalization Agreement and Receives Bridge Financing
8. HemoCue Receives First FDA CLIA Waiver in Diagnostics Industry for Quantitative Point-of-Care Test for Microalbuminuria, a Kidney and Cardiovascular Disease Risk Marker
9. MEDRAD Receives FDA 510(k) Clearance for FDG Infusion System
10. Xenon Receives BIOTECanada Gold Leaf Award
11. Sinovac Receives Healive(R) and Bilive(R) Purchase Orders from Provincial CDCs for Earthquake Disaster Areas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... ... February 17, 2017 , ... Academy of Model Aeronautics ... leading maker of unmanned aircraft systems (UAS), are launching a joint program to ... effectively, and support educational outreach efforts. , AMA and DJI will collaborate on ...
(Date:2/16/2017)... (PRWEB) , ... February 16, 2017 , ... Avomeen & ... The event will be held at Avomeen Analytical Services (4840 Venture Dr., Ann ... MichBio member organization. They provide an opportunity to interact with peers, make new connections ...
(Date:2/16/2017)... , Feb. 16, 2017  MDNA Life Sciences ... development of liquid biopsy tests based on the ... an exclusive license agreement with its first international ... liquid biopsy test for prostate cancer, the Prostate ... . This is the first overseas appointment ...
(Date:2/16/2017)... 16, 2017   Capricor Therapeutics, Inc. ... company developing first-in-class biological therapies for cardiac and ... elected to terminate its license agreement with the ... including Cenderitide. "Our decision to return ... prioritize our efforts to advance our core cell ...
Breaking Biology Technology:
(Date:2/3/2017)... ANTONIO , Feb. 3, 2017  Texas Biomedical Research ... Dr. Larry Schlesinger as the Institute,s new ... Texas Biomed effective May 31, 2017. He is currently the ... Director of the Center for Microbial Interface Biology at Ohio ... Schlesinger as the new President and CEO of Texas Biomed," ...
(Date:2/2/2017)... , Feb. 2, 2017   TapImmune, ... clinical-stage immuno-oncology company specializing in the development of ... the treatment of cancer and metastatic disease, announced ... and GMP manufacturing of a second clinical lot ... targeting folate receptor alpha. The manufactured vaccine product ...
(Date:2/2/2017)... -- Central to its deep commitment to honor the ... Prize Foundation today announced the laureates of the ... in their respective fields of Life Sciences and ... recognized with the 2017 Japan Prize for original ... the advancement of science and technology, but also ...
Breaking Biology News(10 mins):